Accelerated RNA detection using tandem CRISPR nucleases
暂无分享,去创建一个
P. Hsu | K. Pollard | J. Doudna | N. Switz | D. Fletcher | G. Knott | John James Desmarais | D. Savage | B. W. Thornton | E. Charles | S. Son | N. Prywes | P. Fozouni | M. Tan | A. Mok | G. R. Kumar | M. Díaz de León Derby | S. I. Stephens | J. Shu | A. Bhuiya | M. Armstrong | S. Agrawal | D. Smock | E. Dugan | A. Iavarone | T. Liu | L. Lareau | A. M. Escajeda | R. Mcintosh | A. Harris | C. Zhao | S. Jakhanwal | M. Ott | S. Kim | IGI Testing Consortium
[1] Stan J. J. Brouns,et al. SCOPE: Flexible targeting and stringent CARF activation enables type III CRISPR-Cas diagnostics , 2021, bioRxiv.
[2] D. Patel,et al. The Card1 nuclease provides defence during Type III CRISPR immunity , 2021, Nature.
[3] Michael V. D’Ambrosio,et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy , 2020, Cell.
[4] D. Larremore,et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening , 2020, Science Advances.
[5] Matthew P. Taylor,et al. Intrinsic Signal Amplification by Type-III CRISPR-Cas Systems Provides a Sequence-Specific Viral Diagnostic , 2020, medRxiv.
[6] Daniel B Larremore,et al. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. , 2020, The New England journal of medicine.
[7] J. Joung,et al. Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing , 2020, The New England journal of medicine.
[8] J. Doudna,et al. Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation , 2020, The Journal of Biological Chemistry.
[9] V. Šikšnys,et al. Type III-A CRISPR-associated protein Csm6 degrades cyclic hexa-adenylate activator using both CARF and HEPN domains , 2020, Nucleic acids research.
[10] Eric Song,et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets , 2020, Nature Microbiology.
[11] Ru Huang,et al. CRISPR/Cas13a Powered Portable Electrochemiluminescence Chip for Ultrasensitive and Specific MiRNA Detection , 2020, Advanced science.
[12] P. V. Van Caeseele,et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.
[13] Zachary Schiffman,et al. Predicting infectious SARS-CoV-2 from diagnostic samples , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] N.-G. Kim,et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics , 2020, medRxiv.
[15] Guixia Yu,et al. CRISPR-Cas12–based detection of SARS-CoV-2 , 2020, Nature Biotechnology.
[16] Megan L Hochstrasser,et al. Blueprint for a pop-up SARS-CoV-2 testing lab , 2020, Nature Biotechnology.
[17] Jonathan Hall,et al. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6 , 2020, Nature Communications.
[18] M. F. White,et al. The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling , 2020, bioRxiv.
[19] Stan J. J. Brouns,et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants , 2019, Nature Reviews Microbiology.
[20] M. F. White,et al. Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate , 2019, Nature Communications.
[21] Mingxia Feng,et al. Structure of Csx1-cOA4 complex reveals the basis of RNA decay in Type III-B CRISPR-Cas , 2019, Nature Communications.
[22] Roger A. Jones,et al. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA4 Cleavage with ApA>p Formation Terminating RNase Activity. , 2019, Molecular cell.
[23] P. J. Kranzusch,et al. Structure and mechanism of a cyclic trinucleotide-activated bacterial endonuclease mediating bacteriophage immunity , 2019, bioRxiv.
[24] E. Nogales,et al. Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble , 2019, Nature Communications.
[25] M. F. White,et al. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator , 2019, bioRxiv.
[26] Jennifer A. Doudna,et al. CRISPR-Cas guides the future of genetic engineering , 2018, Science.
[27] M. F. White,et al. Ring nucleases deactivate Type III CRISPR ribonucleases by degrading cyclic oligoadenylate , 2018, Nature.
[28] James J. Collins,et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6 , 2018, Science.
[29] Frank Schwede,et al. Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers , 2017, Nature.
[30] D. Burstein,et al. RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes. , 2017, Molecular cell.
[31] Aviv Regev,et al. Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.
[32] Jennifer A. Doudna,et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection , 2016, Nature.
[33] M. Jinek,et al. Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6 , 2016, RNA.
[34] Yunpeng Li,et al. CIDRE: an illumination-correction method for optical microscopy , 2015, Nature Methods.
[35] Olaf Piepenburg,et al. DNA Detection Using Recombination Proteins , 2006, PLoS biology.
[36] T. Notomi,et al. Accelerated reaction by loop-mediated isothermal amplification using loop primers. , 2002, Molecular and cellular probes.
[37] D. Chitwood,et al. Cc-by-nc-nd 4.0 International License , 2022 .